Understanding how specific RAS proteins drive cancer growth
Isoform-specific signaling as a determinant of RAS-driven oncogenesis
This study is looking at how certain RAS proteins behave in cancer and how they help tumors grow, with the goal of finding better treatments for patients with RAS mutations, so they can receive therapies that work best for their specific condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry M. Jackson Fdn for the Adv Mil/med NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project ID | NIH-11015883 on NIH RePORTER |
What this research studies
This research investigates the role of different RAS proteins in cancer, particularly focusing on how they activate various signaling pathways that contribute to tumor growth. By examining RAS mutations, the study aims to identify effective therapeutic strategies that target these pathways, especially in RAS-mutated cancers. The approach involves analyzing the interactions between mutant RAS proteins and their signaling partners to develop combination therapies that can overcome resistance to existing treatments. Patients may benefit from insights that lead to more effective cancer therapies tailored to their specific RAS mutation.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with RAS-mutated cancers, such as those with specific mutations in HRAS or KRAS.
Not a fit: Patients without RAS mutations or those with cancers not driven by RAS signaling may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with RAS-mutated cancers.
How similar studies have performed: Other research has shown promising results in targeting RAS signaling pathways, indicating that this approach may lead to significant advancements in cancer treatment.
Where this research is happening
Bethesda, United States
- Henry M. Jackson Fdn for the Adv Mil/med — Bethesda, United States (Active)
Researchers
- Principal investigator: Kortum, Robert — Henry M. Jackson Fdn for the Adv Mil/med
- Study coordinator: Kortum, Robert
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.